Channel BannerChannel Banner
8VS88bRH4Ww8VS88bRH4Ww

Eloxx Pharmaceuticals and It's Focus on Cystic Fibrosis

294
Socialcounts.Org
Enter Fullscreen (f)
7
likes
0
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

Eloxx Pharmaceuticals and It's Focus on Cystic Fibrosis Analytics Table

Income Estimates for Eloxx Pharmaceuticals and It's Focus on Cystic Fibrosis

Based on this YouTube video's total view count of 294 views and industry-standard rates, the estimated total earning is $0 - $1 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About Eloxx Pharmaceuticals and It's Focus on Cystic Fibrosis

Explore Eloxx Pharmaceuticals and It's Focus on Cystic Fibrosis with 294 views, 7 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals provides an overview of his company and it's focus on cystic fibrosis. Eloxx is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard